CD177 and myeloproliferative disorder: The clinical relevance of HNA-2 (CD177) spans transfusion medicine (TRALI, neonatal immune neutropenia), autoimmune disease [anti-neutrophil cytoplasmic antibody (ANCA) vasculitis], haematological malignancies [diagnosis and prognosis in myeloproliferative neoplasms (MPNs)], and the solid TME (potential carcinogenic functions).